BIT Mining
BTCM
Intchains Group
ICG
Digihost Technology
DGHI
Riot Platforms
RIOT
FRMO CORP
FRMO
US Stock MarketDetailed Quotes
UNCY Unicycive Therapeutics
- 0.5873
- +0.0063+1.08%
Trading Mar 18 10:59 ET
63.68MMarket Cap-1.28P/E (TTM)
0.5938High0.5722Low144.73KVolume0.5722Open0.5810Pre Close84.22KTurnover0.24%Turnover RatioLossP/E (Static)108.42MShares1.600052wk High2.29P/B34.84MFloat Cap0.202052wk Low--Dividend TTM59.32MShs Float8.7300Historical High--Div YieldTTM3.72%Amplitude0.2020Historical Low0.5810Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Unicycive Therapeutics Stock Forum
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
Thursday, 20th February at 7:00 am
LOS ALTOS, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the publication of preclinical data desc...
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
7 minutes ago, 4:00 AM PST
Via GlobeNewswire
UNCY
Share
LOS ALTOS, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the publication of a review on ...
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
Tuesday, 7th January at 7:00 am
LOS ALTOS, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that data from the Company's oxylanthanum carb...
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics
Tuesday, 17th December at 7:00 am
LOS ALTOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that data from the Company's oxylanthanum carbonate (OLC)...
H.C. Wainwright raised the firm’s on Unicycive Therapeutics () to $4 from $2.50 and keeps a Buy rating on the shares following the Q3 report.
Published first on – the ultimate source for real-time, market-moving breaking financ
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
Positive
FDA acceptance of OLC New Drug Application with PDUFA date set for June 28, 2025
Strong patient preference for OLC: 79% preferred it over prior therapy
Successful completion of UNI-494 Phase 1 trial with positive safety profile
Patent granted for UNI-494 valid until 2040
Cash runway extended into 2026 with $32.3M cash position
Reduced net loss to $4.1M from $4.4...
No comment yet